Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01511419Phase 1Completed

Safety Trial of Live Attenuated Influenza (H7N3) Vaccine

Role: collaborator

NCT01982331Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Role: collaborator

NCT02153671Phase 2Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Role: collaborator

NCT01719783Phase 1Completed

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Role: collaborator

NCT03739229Phase 1Unknown

Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine

Role: collaborator

NCT02480101Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

Role: collaborator

All 6 trials loaded